Development of a lipoplex-type mRNA carrier composed of an ionizable lipid with a vitamin E scaffold and the KALA peptide for use as an ex vivo dendritic cell-based cancer vaccine

Tateshita, Naho; Miura, Naoya; Tanaka, Hiroki; Masuda, Takeshi; Ohtsuki, Sumio; Tange, Kota; Nakai, Yoshihisa; Yoshioka, Hiroki; Akita, Hidetaka

doi:10.1016/j.jconrel.2019.08.002

Cited by 66 publications

(49 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tateshita et al regarded lipoplex-type mRNA as a vector to deliver unstable mRNA (in serumcontaining medium) into bone marrow-derived dendritic cells (BMDCs). The results showed prominent OVAspecific cytotoxic T lymphocyte activity in vivo and antitumor effect by expressing the OVA protein [64]. Similarly, as for viral diseases, Joe et al investigated whether intranodally administrated nucleoprotein mRNA vaccine could induce protective immunity.…”

Section: Mechanisms Of Mrna Vaccine-mediated Immunotherapymentioning

confidence: 99%

“…Mechanically, it disrupts the cellular membrane to allow the introduction of mRNA [203]. Parameters like voltage, electroporation solution, density, pulse time, cell number and RNA quantity can optimize the delivery efficiency [64,204]. Even if former investigations have applied the mRNA electroporation to inflammatory diseases, most of the electroporation-related mRNA vaccine studies are about cancer.…”

Section: Mrna Vaccines In Viral Diseasesmentioning

confidence: 99%

See 1 more Smart Citation

mRNA vaccine: a potential therapeutic strategy

Wei¹,

et al. 2021

View full text Add to dashboard Cite

AbstractmRNA vaccines have tremendous potential to fight against cancer and viral diseases due to superiorities in safety, efficacy and industrial production. In recent decades, we have witnessed the development of different kinds of mRNAs by sequence optimization to overcome the disadvantage of excessive mRNA immunogenicity, instability and inefficiency. Based on the immunological study, mRNA vaccines are coupled with immunologic adjuvant and various delivery strategies. Except for sequence optimization, the assistance of mRNA-delivering strategies is another method to stabilize mRNAs and improve their efficacy. The understanding of increasing the antigen reactiveness gains insight into mRNA-induced innate immunity and adaptive immunity without antibody-dependent enhancement activity. Therefore, to address the problem, scientists further exploited carrier-based mRNA vaccines (lipid-based delivery, polymer-based delivery, peptide-based delivery, virus-like replicon particle and cationic nanoemulsion), naked mRNA vaccines and dendritic cells-based mRNA vaccines. The article will discuss the molecular biology of mRNA vaccines and underlying anti-virus and anti-tumor mechanisms, with an introduction of their immunological phenomena, delivery strategies, their importance on Corona Virus Disease 2019 (COVID-19) and related clinical trials against cancer and viral diseases. Finally, we will discuss the challenge of mRNA vaccines against bacterial and parasitic diseases.

show abstract

Section: Mechanisms Of Mrna Vaccine-mediated Immunotherapymentioning

confidence: 99%

Section: Mrna Vaccines In Viral Diseasesmentioning

confidence: 99%

mRNA vaccine: a potential therapeutic strategy

Wei¹,

et al. 2021

View full text Add to dashboard Cite

show abstract

“…The combined effect of the ionizable lipid YSK05 and GALA improved the endosome escape as compared to a control system (composed of the cationic lipid DOTMA and GALA). In another work, the virus‐derived peptide KALA was conjugated to a lipid chain and included in LNPs structure for mRNA delivery 129 . The combination of KALA and ionizable lipids promoted the cell uptake and mRNA translation compared to controls (LNPs equipped with another peptide, or LNPs formulated without ionizable lipids).…”

Section: How Do Viruses Overcome the Endosomal Membrane?mentioning

confidence: 99%

Cytosolic delivery of nucleic acids: The case of ionizable lipid nanoparticles

Schlich

Palomba

Costabile

et al. 2021

Bioengineering & Transla Med

143

131

View full text Add to dashboard Cite

show abstract

“…Other parameters, including electroporation solution, pulse time, cell number, density, and RNA quantity should also be optimized. Under the optimized condition, the mRNA-loaded DCs should maintain their biological properties, including cell phenotypes, maturation status, cytokine secreting ability, and antigen presentation function (Tuyaerts et al 2002;Tateshita et al 2019). Besides electroporation, lipid-derived carriers were also tested to deliver mRNA into DCs for the preparation of DC-based mRNA vaccines (De Temmerman et al 2011;Tateshita et al 2019).…”

Section: Dendritic Cells-based Mrna Vaccinesmentioning

confidence: 99%

Formulation and Delivery Technologies for mRNA Vaccines

Zeng

Zhang

Walker

et al. 2020

Current Topics in Microbiology and Immunology

114

119

View full text Add to dashboard Cite

mRNA vaccines have become a versatile technology for the prevention of infectious diseases and the treatment of cancers. In the vaccination process, mRNA formulation and delivery strategies facilitate effective expression and presentation of antigens, and immune stimulation. mRNA vaccines have been delivered in various formats: encapsulation by delivery carriers, such as lipid nanoparticles, polymers, peptides, free mRNA in solution, and ex vivo through dendritic cells. Appropriate delivery materials and formulation methods often boost the vaccine efficacy which is also influenced by the selection of a proper administration route. Co-delivery of multiple mRNAs enables synergistic effects and further enhances immunity in some cases. In this chapter, we overview the recent progress and existing challenges in the formulation and delivery technologies of mRNA vaccines with perspectives for future development.

show abstract

Development of a lipoplex-type mRNA carrier composed of an ionizable lipid with a vitamin E scaffold and the KALA peptide for use as an ex vivo dendritic cell-based cancer vaccine

Cited by 66 publications

References 34 publications

mRNA vaccine: a potential therapeutic strategy

mRNA vaccine: a potential therapeutic strategy

Cytosolic delivery of nucleic acids: The case of ionizable lipid nanoparticles

Formulation and Delivery Technologies for mRNA Vaccines

Contact Info

Product

Resources

About